Zenotech laboratories has officially filed its postal ballot results with BSE Limited, confirming the successful appointment of Mr. Nikkhil Venilal Kothhari as an Independent Director. The pharmaceutical company submitted the comprehensive report on March 12, 2026, following the conclusion of the remote e-voting process on March 11, 2026.

BSE Filing and Regulatory Compliance

The company submitted its formal report to BSE Limited under Regulation 44(3) of SEBI Listing Regulations, providing detailed documentation of the postal ballot process. The filing included the scrutinizer's report, voting results, and complete compliance documentation for the special resolution.

Comprehensive Voting Results Analysis

The postal ballot demonstrated exceptional shareholder support with 99.90% approval for the appointment. The voting process saw participation from 68 members representing 69.12% of the total shareholding.

Category-wise Shareholder Participation

The voting pattern revealed complete participation from the promoter group while public shareholders showed selective engagement in the governance process.

Process Timeline and Documentation

The postal ballot process followed strict regulatory timelines with comprehensive documentation. The company ensured full compliance with Companies Act, 2013 provisions and SEBI Listing Regulations throughout the process.

Corporate Governance and Transparency

The appointment strengthens Zenotech Laboratories' board composition and demonstrates the company's commitment to robust corporate governance practices. The overwhelming shareholder approval reflects confidence in the strategic direction and board enhancement initiatives.

The results have been made available across multiple platforms including the company's registered office notice board, NSDL e-voting website, and the company's official website at www.zenotechlab.com , ensuring complete transparency and stakeholder accessibility.

Zenotech Laboratories Limited announced its unaudited standalone financial results for the quarter ended December 31, 2025, alongside significant board changes during its meeting held on January 23, 2026.

Financial Performance Overview

The company delivered a strong financial performance in Q3FY26, with key metrics showing improvement across several parameters:

For the nine months ended December 31, 2025, total income reached ₹3,544.55 lakhs compared to ₹3,197.16 lakhs in the corresponding period last year, representing an increase of 10.87%. However, net profit for the nine-month period was ₹207.87 lakhs, lower than ₹432.99 lakhs in the previous year.

Exceptional Items Impact

The company reported exceptional items of ₹29.89 lakhs (expense) in Q3FY26, primarily due to increased gratuity and leave encashment liability arising from the implementation of new Labour Codes notified by the Government of India on November 21, 2025. These codes consolidate twenty-nine existing labour laws and introduce enhanced employee benefits.

Board Leadership Changes

The Board approved the appointment of Mr. Nikkhil Venilal Kothhari (DIN: 11501373) as Additional Independent Director for a five-year term, effective January 23, 2026, subject to shareholder approval. Mr. Kothhari brings extensive experience as a Fellow Chartered Accountant with a Ph.D. in Bancassurance from Mumbai University and 40 years of professional experience in accounting, taxation, audit, and regulatory compliance.

Simultaneously, Mr. Chintan Jitendra Shah's second tenure as Independent Director concluded on January 26, 2026. The Board acknowledged his valuable contributions during his tenure as Independent Director and Chairman of the Nomination and Remuneration Committee.

Committee Reconstitution

Effective January 27, 2026, the company reconstituted all three board committees:

Audit Committee:

• Chairperson: Smt. Jagruti Prashant Sheth (Independent Director)
• Members: Mr. Jignesh Anantray Goradia (Director), Mr. Premal Hemant Gandhi (Independent Director)

Nomination and Remuneration Committee:

• Chairman: Mr. Premal Hemant Gandhi (Independent Director)
• Members: Mr. Jignesh Anantray Goradia (Director), Smt. Jagruti Prashant Sheth (Independent Director)

Stakeholders Relationship Committee:

• Chairman: Mr. Jignesh Anantray Goradia (Director)
• Members: Mr. Premal Hemant Gandhi (Independent Director), Smt. Jagruti Prashant Sheth (Independent Director)

Operational Highlights

The company continues to operate in the pharmaceuticals segment as its sole reportable business. Other operating income of ₹102.76 lakhs in Q3FY26 primarily relates to rentals from the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities. Employee benefit expenses increased to ₹402.17 lakhs in Q3FY26 from ₹317.90 lakhs in the corresponding quarter last year, reflecting the company's continued investment in human resources.